PF07104091

CAS No. 2460249-19-6

PF07104091( PF-07104091 )

Catalog No. M28851 CAS No. 2460249-19-6

PF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 915 In Stock
2MG 519 In Stock
5MG 824 In Stock
10MG 1207 In Stock
25MG 1796 In Stock
50MG 2372 In Stock
100MG 3190 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    PF07104091
  • Note
    Research use only, not for human use.
  • Brief Description
    PF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.
  • Description
    PF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    PF-07104091
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2460249-19-6
  • Formula Weight
    404.46
  • Molecular Formula
    C19H28N6O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N(C(=O)C1=CC(COC)=NN1C)C2=CC(=NN2)[C@@H]3C[C@H](OC(NC(C)C)=O)CC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Yamaguchi T, et al. Determination of 7-chloro-3-(4-methyl-1-piperazinyl)-4h-1,2,4-benzothiadiazine-1,1-dioxide (DU-717) in plasma using electron-capture gas chromatography. J Chromatogr. 1978 Oct 11;160(1):181-90.
molnova catalog
related products
  • Abemaciclib metaboli...

    Abemaciclib metabolite M20 is an active metabolite of Abemaciclib.

  • Cdc7 inhibitor 7c

    A highly potent, selective and time-dependent Cdc7 kinase inhibitor with IC50 of 0.7 nM with slow dissociation property, with 200-fold and >14,000-fold selectivity over CDK2 and ROCK1, respectively.

  • BS-194

    BS-194 is a potent, selective, orally bioactive CDK2 inhibitor with IC50 of 2.4 nM, displays 140-fold selectivity over CDK7 (IC50=378 nM); weakly inhibits CDK1, CDK5, CDK7, and CDK9 with IC50 of 30, 30, 250, and 90 nM.